{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:00:17Z","timestamp":1790888417542,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"VA ORD","doi-asserted-by":"publisher","award":["I01BX003895"],"award-info":[{"award-number":["I01BX003895"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["Q2 P30CA093373"],"award-info":[{"award-number":["Q2 P30CA093373"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016953","name":"Comprehensive Cancer Center, University of California, Davis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cpt.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:33:42Z","timestamp":1770165222000},"page":"412-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrin \u03b13 (ITGA3) expression across breast cancer subtypes: Prognosis and therapeutic relevance"],"prefix":"10.1016","volume":"4","author":[{"given":"Weijie","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-0274","authenticated-orcid":false,"given":"Hongyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reggie R.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7289-4395","authenticated-orcid":false,"given":"Dingning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-8217","authenticated-orcid":false,"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7422-3520","authenticated-orcid":false,"given":"Tianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2026.01.004_bib1","first-page":"287","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.cpt.2026.01.004_bib2","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpt.2026.01.004_bib3","series-title":"Breast cancer facts & figures 2024-2025","year":"2024"},{"key":"10.1016\/j.cpt.2026.01.004_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2014.12.005","article-title":"Triple positive breast cancer: a distinct subtype?","volume":"41","author":"Vici","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cpt.2026.01.004_bib5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clbc.2023.03.007","article-title":"Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics","volume":"23","author":"O'Shaughnessy","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis","volume":"10","author":"Benitez Fuentes","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpt.2026.01.004_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ijc.2910640407","article-title":"Expression of alpha 3 beta 1 integrin receptor and its ligands in human lung tumors","volume":"64","author":"Bartolazzi","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.prp.2009.07.005","article-title":"Expression profiling of integrins in lung cancer cells","volume":"205","author":"Guo","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.cpt.2026.01.004_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-019-0740-7","article-title":"High-affinity peptide ligand LXY30 for targeting alpha3beta1 integrin in non-small cell lung cancer","volume":"12","author":"Xiao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cpt.2026.01.004_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cpt.2026.01.004_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin targeted therapeutics","volume":"1","author":"Millard","year":"2011","journal-title":"Theranostics"},{"key":"10.1016\/j.cpt.2026.01.004_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.1758709","article-title":"Genetic and cell biological analysis of integrin outside-in signaling","volume":"23","author":"Legate","year":"2009","journal-title":"Genes Dev"},{"key":"10.1016\/j.cpt.2026.01.004_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1021\/bi401596q","article-title":"Integrin cytoplasmic tail interactions","volume":"53","author":"Morse","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.cpt.2026.01.004_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1349-7006.2004.tb03195.x","article-title":"Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line","volume":"95","author":"Yoshimasu","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cpt.2026.01.004_bib16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.21037\/tlcr-19-633","article-title":"High integrin alpha3 expression is associated with poor prognosis in patients with non-small cell lung cancer","volume":"9","author":"Li","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cpt.2026.01.004_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/1541-7786.MCR-13-0184","article-title":"Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma","volume":"12","author":"Zhou","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.cpt.2026.01.004_bib18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/cas.12220","article-title":"Identification of integrin alpha3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes","volume":"104","author":"Shirakihara","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cpt.2026.01.004_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fonc.2020.00036","article-title":"High expression of integrin alpha3 predicts poor prognosis and promotes tumor metastasis and angiogenesis by activating the c-Src\/extracellular signal-regulated protein kinase\/focal adhesion kinase signaling pathway in cervical cancer","volume":"10","author":"Du","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.01.004_bib20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/bjc.2013.218","article-title":"Integrin alpha3 is overexpressed in glioma stem-like cells and promotes invasion","volume":"108","author":"Nakada","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3","article-title":"The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity","volume":"87","author":"Morini","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib22","doi-asserted-by":"crossref","first-page":"658547","DOI":"10.3389\/fonc.2021.658547","article-title":"ITGA3 is associated with immune cell infiltration and serves as a favorable prognostic biomarker for breast cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.01.004_bib23","doi-asserted-by":"crossref","first-page":"144396","DOI":"10.1016\/j.gene.2020.144396","article-title":"ITGA3 interacts with VASP to regulate stemness and epithelial-mesenchymal transition of breast cancer cells","volume":"734","author":"Zhang","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.cpt.2026.01.004_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/cancers15030924","article-title":"Labyrinthin expression is associated with poor prognosis in patients with non-small-cell lung cancer","volume":"15","author":"Ma","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2026.01.004_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cpt.2026.01.004_bib26","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancer refine their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.01.004_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cpt.2026.01.004_bib28","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/ijc.32369","article-title":"ROCplot.org: validating predictive biomarkers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients","volume":"145","author":"Fekete","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/1471-2407-14-459","article-title":"Expression of integrin alpha3beta1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer","volume":"14","author":"Aggarwal","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","article-title":"Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance","volume":"40","author":"Yousefi","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.cpt.2026.01.004_bib31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/14728222.2011.609557","article-title":"Integrin alpha3beta1 as a breast cancer target","volume":"15","author":"Subbaram","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.cpt.2026.01.004_bib32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/cancers13030480","article-title":"Integrin alpha3beta1 promotes invasive and metastatic properties of breast cancer cells through induction of the Brn-2 transcription factor","volume":"13","author":"Miskin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2026.01.004_bib33","first-page":"455","article-title":"CD151 Promotes Cancer Progression in Triple-Negative Breast Cancer by Inducing EMT through the MAPK Signaling Pathway","volume":"17","author":"Lv","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.cpt.2026.01.004_bib34","doi-asserted-by":"crossref","first-page":"108458","DOI":"10.1016\/j.pharmthera.2023.108458","article-title":"Integrins in cancer: emerging mechanisms and therapeutic opportunities","volume":"247","author":"Liu","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cpt.2026.01.004_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13058-019-1146-8","article-title":"Absence of integrin alpha3beta1 promotes the progression of HER2-driven breast cancer in vivo","volume":"21","author":"Ramovs","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cpt.2026.01.004_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-021-01998-4","article-title":"CD151 drives cancer progression depending on integrin alpha3beta1 through EGFR signaling in non-small cell lung cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.cpt.2026.01.004_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/path.1711650106","article-title":"Low expression of beta 1, alpha 2 and alpha 3 subunits of VLA integrins in malignant mammary tumours","volume":"165","author":"Pignatelli","year":"1991","journal-title":"J Pathol"},{"key":"10.1016\/j.cpt.2026.01.004_bib38","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/bjc.2015.344","article-title":"Lack of CD151\/integrin alpha3beta1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancer","volume":"113","author":"Romanska","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cpt.2026.01.004_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0039-6060(05)80236-3","article-title":"Integrin expression in primary breast cancer and its relation to axillary nodal status","volume":"117","author":"Gui","year":"1995","journal-title":"Surgery"},{"key":"10.1016\/j.cpt.2026.01.004_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-016-0165-z","article-title":"Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of alpha3 integrin-expressing human tumors","volume":"6","author":"Xiao","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.cpt.2026.01.004_bib41","doi-asserted-by":"crossref","first-page":"113745","DOI":"10.1016\/j.biopha.2022.113745","article-title":"Integrin-mediated cancer progression as a specific target in clinical therapy","volume":"155","author":"Chen","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cpt.2026.01.004_bib42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1535-7163.MCT-23-0458","article-title":"Simvastatin overcomes resistance to tyrosine kinase inhibitors in patient-derived, oncogene-driven lung adenocarcinoma models","volume":"23","author":"Ma","year":"2024","journal-title":"Mol Cancer Therapeut"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:26:48Z","timestamp":1790886408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713226000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2949713226000042"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2026.01.004","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrin \u03b13 (ITGA3) expression across breast cancer subtypes: Prognosis and therapeutic relevance","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}